

17 March 2020

ASX ANNOUNCEMENT

COVID-19 Impact on MVP

Medical Developments International Limited (ASX: MVP) advises that at this stage the potential negative impact of the COVID 19 virus on its business appears limited. Specifically:

- MVP has been building stock to cater for an anticipated increase in sales throughout CY20;
- MVP has sufficient stocks of raw materials and finished goods on hand to meet forecast demand;
- key suppliers remain 'open for business' and MVP continues to receive supplies and to fulfil orders;
- whilst some raw material stock is directly imported from China, those materials are held in sufficient quantities to maintain production throughout CY20;
- MVP has not (to date) experienced a decline in demand for its pharmaceutical and medical product;
- clinical programs underway in China, UK, Europe and South Korea are either on provisional hold or being delayed as local medical authorities and services in these countries focus on COVID-19;
- at this stage we have not been advised of any delays from the FDA;
- MVP continues to develop contingency plans to manage the ongoing risk faced by the business.
- Staff are avoiding any non-essential travel and rostering has been implemented.
- A very small level of sales to China from the Company's Veterinary business are negatively impacted.

Authorised for release by MVP Chairman, David Williams.

Enquiries:

David Williams
Chairman
Medical Developments International Ltd
+61 (0) 414 383 593

John Sharman
Chief Executive Officer
Medical Developments International Ltd
+61 (3) 9547 1888



About Pentrox®

Penthrox is a fast onset, non-opioid analgesic indicated for pain relief by self-administration in patients with trauma and those requiring analgesia for surgical procedures. Penthrox is now approved for sale in more than 40 countries and has been used safely and effectively for more than 40 years in Australia with more than 7.0 million units sold. There is growing interest in Penthrox being used in patients undergoing investigatory procedures, as well as operational procedures such as colonoscopy.

About Medical Developments International Ltd

MVP is an Australian company delivering emergency medical solutions dedicated to improving patient outcomes. MVP is a leader in emergency pain relief and respiratory products. The Company manufactures Pentrox®, a fast-acting trauma & emergency pain relief product. It is used in Australian Hospitals including Emergency Departments, Australian Ambulance Services, the Australian Defence Forces, Sports Medicine and for analgesia during short surgical procedures such as Dental and Cosmetic surgery as well as in other medical applications. MVP is expanding internationally and manufactures a range of world-leading Asthma respiratory devices.